Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Retrotransposon insertions can initiate colorectal cancer and are associated with poor survival.

Cajuso T, Sulo P, Tanskanen T, Katainen R, Taira A, Hänninen UA, Kondelin J, Forsström L, Välimäki N, Aavikko M, Kaasinen E, Ristimäki A, Koskensalo S, Lepistö A, Renkonen-Sinisalo L, Seppälä T, Kuopio T, Böhm J, Mecklin JP, Kilpivaara O, Pitkänen E, Palin K, Aaltonen LA.

Nat Commun. 2019 Sep 6;10(1):4022. doi: 10.1038/s41467-019-11770-0.

2.

L1TD1 - a prognostic marker for colon cancer.

Chakroborty D, Emani MR, Klén R, Böckelman C, Hagström J, Haglund C, Ristimäki A, Lahesmaa R, Elo LL.

BMC Cancer. 2019 Jul 23;19(1):727. doi: 10.1186/s12885-019-5952-2.

3.

Notum produced by Paneth cells attenuates regeneration of aged intestinal epithelium.

Pentinmikko N, Iqbal S, Mana M, Andersson S, Cognetta AB 3rd, Suciu RM, Roper J, Luopajärvi K, Markelin E, Gopalakrishnan S, Smolander OP, Naranjo S, Saarinen T, Juuti A, Pietiläinen K, Auvinen P, Ristimäki A, Gupta N, Tammela T, Jacks T, Sabatini DM, Cravatt BF, Yilmaz ÖH, Katajisto P.

Nature. 2019 Jul;571(7765):398-402. doi: 10.1038/s41586-019-1383-0. Epub 2019 Jul 10.

PMID:
31292548
4.

Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study.

Dufraing K, van Krieken JH, De Hertogh G, Hoefler G, Oniscu A, Kuhlmann TP, Weichert W, Marchiò C, Ristimäki A, Ryška A, Scoazec JY, Dequeker E.

Histopathology. 2019 Sep;75(3):312-319. doi: 10.1111/his.13891. Epub 2019 Jul 18.

PMID:
31054167
5.

BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital.

Kelppe J, Thorén H, Ristimäki A, Haglund C, Sorsa T, Hagström J.

Oral Dis. 2019 May;25(4):1169-1174. doi: 10.1111/odi.13072. Epub 2019 Mar 19.

PMID:
30811720
6.

Finnish National Esophago-Gastric Cancer Cohort (FINEGO) for studying outcomes after oesophageal and gastric cancer surgery: a protocol for a retrospective, population-based, nationwide cohort study in Finland.

Kauppila JH, Ohtonen P, Karttunen TJ, Kokkola A, Laine S, Rantanen T, Ristimäki A, Räsänen JV, Saarnio J, Sihvo E, Toikkanen V, Tyrväinen T.

BMJ Open. 2019 Jan 15;9(1):e024094. doi: 10.1136/bmjopen-2018-024094.

7.

A High Prevalence of Gastrointestinal Manifestations in Common Variable Immunodeficiency.

Pikkarainen S, Martelius T, Ristimäki A, Siitonen S, Seppänen MRJ, Färkkilä M.

Am J Gastroenterol. 2019 Apr;114(4):648-655. doi: 10.14309/ajg.0000000000000140.

8.

DNA methylation changes and somatic mutations as tumorigenic events in Lynch syndrome-associated adenomas retaining mismatch repair protein expression.

Mäki-Nevala S, Valo S, Ristimäki A, Sarhadi V, Knuutila S, Nyström M, Renkonen-Sinisalo L, Lepistö A, Mecklin JP, Peltomäki P.

EBioMedicine. 2019 Jan;39:280-291. doi: 10.1016/j.ebiom.2018.12.018. Epub 2018 Dec 18.

9.

Biallelic germline nonsense variant of MLH3 underlies polyposis predisposition.

Olkinuora A, Nieminen TT, Mårtensson E, Rohlin A, Ristimäki A, Koskenvuo L, Lepistö A; Swedish Extended Genetic Analysis of Colorectal Neoplasia (SWEN) Study Group, Gebre-Medhin S, Nordling M, Peltomäki P.

Genet Med. 2019 Aug;21(8):1868-1873. doi: 10.1038/s41436-018-0405-x. Epub 2018 Dec 21.

PMID:
30573798
10.

The Mutational Profile of Unicystic Ameloblastoma.

Heikinheimo K, Huhtala JM, Thiel A, Kurppa KJ, Heikinheimo H, Kovac M, Kragelund C, Warfvinge G, Dawson H, Elenius K, Ristimäki A, Baumhoer D, Morgan PR.

J Dent Res. 2019 Jan;98(1):54-60. doi: 10.1177/0022034518798810. Epub 2018 Sep 14.

PMID:
30216733
11.

Contribution of allelic imbalance to colorectal cancer.

Palin K, Pitkänen E, Turunen M, Sahu B, Pihlajamaa P, Kivioja T, Kaasinen E, Välimäki N, Hänninen UA, Cajuso T, Aavikko M, Tuupanen S, Kilpivaara O, van den Berg L, Kondelin J, Tanskanen T, Katainen R, Grau M, Rauanheimo H, Plaketti RM, Taira A, Sulo P, Hartonen T, Dave K, Schmierer B, Botla S, Sokolova M, Vähärautio A, Gladysz K, Ongen H, Dermitzakis E, Bramsen JB, Ørntoft TF, Andersen CL, Ristimäki A, Lepistö A, Renkonen-Sinisalo L, Mecklin JP, Taipale J, Aaltonen LA.

Nat Commun. 2018 Sep 10;9(1):3664. doi: 10.1038/s41467-018-06132-1.

12.

Glycomic Profiling Highlights Increased Fucosylation in Pseudomyxoma Peritonei.

Saarinen L, Nummela P, Leinonen H, Heiskanen A, Thiel A, Haglund C, Lepistö A, Satomaa T, Hautaniemi S, Ristimäki A.

Mol Cell Proteomics. 2018 Nov;17(11):2107-2118. doi: 10.1074/mcp.RA118.000615. Epub 2018 Aug 2.

PMID:
30072579
13.

Colorectal cancer patients with different C-reactive protein levels and 5-year survival times can be differentiated with quantitative serum proteomics.

Holm M, Saraswat M, Joenväärä S, Ristimäki A, Haglund C, Renkonen R.

PLoS One. 2018 Apr 9;13(4):e0195354. doi: 10.1371/journal.pone.0195354. eCollection 2018.

14.

Exome-wide somatic mutation characterization of small bowel adenocarcinoma.

Hänninen UA, Katainen R, Tanskanen T, Plaketti RM, Laine R, Hamberg J, Ristimäki A, Pukkala E, Taipale M, Mecklin JP, Forsström LM, Pitkänen E, Palin K, Välimäki N, Mäkinen N, Aaltonen LA.

PLoS Genet. 2018 Mar 9;14(3):e1007200. doi: 10.1371/journal.pgen.1007200. eCollection 2018 Mar.

15.

Does a histologically inflamed resection margin increase postoperative complications in patients with Crohn's disease?

Aaltonen G, Ristimäki A, Keränen I, Carpelan-Holmström M, Lepistö A.

Scand J Gastroenterol. 2018 Mar;53(3):279-283. doi: 10.1080/00365521.2018.1435717. Epub 2018 Feb 12.

PMID:
29431516
16.

Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.

Puolanne AM, Kolho KL, Alfthan H, Ristimäki A, Mustonen H, Färkkilä M.

Dig Dis Sci. 2017 Nov;62(11):3123-3130. doi: 10.1007/s10620-017-4770-0. Epub 2017 Sep 25.

PMID:
28948412
17.

A hamartoma presenting as an intramural upper oesophageal tumour.

Räsänen J, Ilonen I, Ristimäki A, Salo JA, Mäkitie AA.

J Thorac Dis. 2017 Aug;9(8):E698-E701. doi: 10.21037/jtd.2017.07.12.

18.

Comparison of sporadic and FAP-associated desmoid-type fibromatoses.

Koskenvuo L, Ristimäki A, Lepistö A.

J Surg Oncol. 2017 Nov;116(6):716-721. doi: 10.1002/jso.24699. Epub 2017 Jun 1.

PMID:
28570749
19.

Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.

Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, El Zimaity H, Fléjou JF, Hansen TP, Hartmann A, Kakar S, Langner C, Nagtegaal I, Puppa G, Riddell R, Ristimäki A, Sheahan K, Smyrk T, Sugihara K, Terris B, Ueno H, Vieth M, Zlobec I, Quirke P.

Mod Pathol. 2017 Sep;30(9):1299-1311. doi: 10.1038/modpathol.2017.46. Epub 2017 May 26. Review.

20.

Multiple components of PKA and TGF-β pathways are mutated in pseudomyxoma peritonei.

Saarinen L, Nummela P, Thiel A, Lehtonen R, Järvinen P, Järvinen H, Aaltonen LA, Lepistö A, Hautaniemi S, Ristimäki A.

PLoS One. 2017 Apr 20;12(4):e0174898. doi: 10.1371/journal.pone.0174898. eCollection 2017.

21.

Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib.

Peltola KJ, Penttilä P, Rautiola J, Joensuu H, Hänninen E, Ristimäki A, Bono P.

Clin Genitourin Cancer. 2017 Aug;15(4):487-494. doi: 10.1016/j.clgc.2017.01.021. Epub 2017 Feb 1.

PMID:
28237182
22.

Carbonic anhydrase II: a novel biomarker for pseudomyxoma peritonei.

Järvinen P, Kivelä AJ, Nummela P, Lepistö A, Ristimäki A, Parkkila S.

APMIS. 2017 Mar;125(3):207-212. doi: 10.1111/apm.12653.

PMID:
28233447
23.

Ring melanoma of the anterior chamber angle as a mimicker of pigmentary glaucoma.

Stadigh A, Puska P, Vesti E, Ristimäki A, Turunen JA, Kivelä TT.

Surv Ophthalmol. 2017 Sep - Oct;62(5):670-676. doi: 10.1016/j.survophthal.2017.01.007. Epub 2017 Feb 1. Review.

PMID:
28159633
24.

EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.

Ålgars A, Sundström J, Lintunen M, Jokilehto T, Kytölä S, Kaare M, Vainionpää R, Orpana A, Österlund P, Ristimäki A, Carpen O, Ristamäki R.

Int J Cancer. 2017 Feb 15;140(4):922-929. doi: 10.1002/ijc.30507. Epub 2016 Nov 23.

25.

Oncological results of extended resection for locally advanced rectal cancer: the value of postirradiation MRI in predicting local recurrence.

Räsänen M, Ristimäki A, Savolainen R, Renkonen-Sinisalo L, Lepistö A.

Colorectal Dis. 2017 Apr;19(4):339-348. doi: 10.1111/codi.13513.

PMID:
27620502
26.

[What will determine the first-line treatment of a patient with rectal cancer?].

Lepistö A, Kouri M, Savolainen R, Ristimäki A.

Duodecim. 2016;132(12):1185-93. Review. Finnish.

PMID:
27483636
27.

[Multidisciplinary tailoring of therapy of metastatic colon cancer].

Österlund P, Isoniemi H, Scheinin T, Ristimäki A, Lantto E.

Duodecim. 2016;132(12):1177-84. Review. Finnish.

PMID:
27483635
28.

Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease.

Puolanne AM, Kolho KL, Alfthan H, Ristimäki A, Mustonen H, Färkkilä M.

Eur J Clin Invest. 2016 Oct;46(10):825-32. doi: 10.1111/eci.12660. Epub 2016 Sep 6.

PMID:
27438629
29.

HuR in pheochromocytomas and paragangliomas - overexpression in verified malignant tumors.

Leijon H, Salmenkivi K, Heiskanen I, Hagström J, Louhimo J, Heikkilä P, Ristimäki A, Paavonen T, Metso S, Mäenpää H, Haglund C, Arola J.

APMIS. 2016 Sep;124(9):757-63. doi: 10.1111/apm.12571. Epub 2016 Jun 30.

PMID:
27357268
30.

Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.

Rautiola J, Lampinen A, Mirtti T, Ristimäki A, Joensuu H, Bono P, Saharinen P.

PLoS One. 2016 Apr 21;11(4):e0153745. doi: 10.1371/journal.pone.0153745. eCollection 2016.

31.

Nrf2/Keap1 Pathway and Expression of Oxidative Stress Lesions 8-hydroxy-2'-deoxyguanosine and Nitrotyrosine in Melanoma.

Hintsala HR, Jokinen E, Haapasaari KM, Moza M, Ristimäki A, Soini Y, Koivunen J, Karihtala P.

Anticancer Res. 2016 Apr;36(4):1497-506.

PMID:
27069125
32.

Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei.

Nummela P, Leinonen H, Järvinen P, Thiel A, Järvinen H, Lepistö A, Ristimäki A.

Hum Pathol. 2016 Aug;54:47-54. doi: 10.1016/j.humpath.2016.02.022. Epub 2016 Mar 30.

PMID:
27038681
33.

Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.

Ranki T, Pesonen S, Hemminki A, Partanen K, Kairemo K, Alanko T, Lundin J, Linder N, Turkki R, Ristimäki A, Jäger E, Karbach J, Wahle C, Kankainen M, Backman C, von Euler M, Haavisto E, Hakonen T, Heiskanen R, Jaderberg M, Juhila J, Priha P, Suoranta L, Vassilev L, Vuolanto A, Joensuu T.

J Immunother Cancer. 2016 Mar 15;4:17. doi: 10.1186/s40425-016-0121-5. eCollection 2016.

34.

Desmoid tumor patients carry an elevated risk of familial adenomatous polyposis.

Koskenvuo L, Peltomäki P, Renkonen-Sinisalo L, Gylling A, Nieminen TT, Ristimäki A, Lepistö A.

J Surg Oncol. 2016 Feb;113(2):209-12. doi: 10.1002/jso.24117. Epub 2015 Dec 10.

PMID:
26663236
35.

A prospective randomised study of dense Infinity cytological brush versus regularly used brush in pancreaticobiliary malignancy.

Kylänpää L, Boyd S, Ristimäki A, Lindström O, Udd M, Halttunen J.

Scand J Gastroenterol. 2016;51(5):590-3. doi: 10.3109/00365521.2015.1121514. Epub 2015 Dec 7.

PMID:
26642244
36.

Diminished salivary epidermal growth factor secretion: a link between Sjögren's syndrome and autoimmune gastritis?

Koskenpato K, Ainola M, Przybyla B, Kouri VP, Virkki L, Koskenpato J, Ristimäki A, Konttinen YT.

Scand J Rheumatol. 2016;45(2):118-21. doi: 10.3109/03009742.2015.1072243. Epub 2015 Sep 23.

PMID:
26399281
37.

Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.

Taipale K, Liikanen I, Juhila J, Turkki R, Tähtinen S, Kankainen M, Vassilev L, Ristimäki A, Koski A, Kanerva A, Diaconu I, Cerullo V, Vähä-Koskela M, Oksanen M, Linder N, Joensuu T, Lundin J, Hemminki A.

Mol Ther. 2016 Feb;24(1):175-83. doi: 10.1038/mt.2015.143. Epub 2015 Aug 27.

38.

DNA hypermethylation appears early and shows increased frequency with dysplasia in Lynch syndrome-associated colorectal adenomas and carcinomas.

Valo S, Kaur S, Ristimäki A, Renkonen-Sinisalo L, Järvinen H, Mecklin JP, Nyström M, Peltomäki P.

Clin Epigenetics. 2015 Jul 22;7:71. doi: 10.1186/s13148-015-0102-4. eCollection 2015.

39.

Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer.

Vassilev L, Ranki T, Joensuu T, Jäger E, Karbach J, Wahle C, Partanen K, Kairemo K, Alanko T, Turkki R, Linder N, Lundin J, Ristimäki A, Kankainen M, Hemminki A, Backman C, Dienel K, von Euler M, Haavisto E, Hakonen T, Juhila J, Jäderberg M, Priha P, Vuolanto A, Pesonen S.

Oncoimmunology. 2015 Apr 1;4(7):e1017702. eCollection 2015 Jul.

40.

Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.

Seppälä TT, Böhm JP, Friman M, Lahtinen L, Väyrynen VM, Liipo TK, Ristimäki AP, Kairaluoma MV, Kellokumpu IH, Kuopio TH, Mecklin JP.

Br J Cancer. 2015 Jun 9;112(12):1966-75. doi: 10.1038/bjc.2015.160. Epub 2015 May 14.

41.

Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization.

Ranki T, Joensuu T, Jäger E, Karbach J, Wahle C, Kairemo K, Alanko T, Partanen K, Turkki R, Linder N, Lundin J, Ristimäki A, Kankainen M, Hemminki A, Backman C, Dienel K, von Euler M, Haavisto E, Hakonen T, Juhila J, Jaderberg M, Priha P, Vassilev L, Vuolanto A, Pesonen S.

Oncoimmunology. 2014 Dec 15;3(10):e958937. eCollection 2014 Nov.

42.

Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.

Hemminki O, Parviainen S, Juhila J, Turkki R, Linder N, Lundin J, Kankainen M, Ristimäki A, Koski A, Liikanen I, Oksanen M, Nettelbeck DM, Kairemo K, Partanen K, Joensuu T, Kanerva A, Hemminki A.

Oncotarget. 2015 Feb 28;6(6):4467-81.

43.

Targeted therapy in gastric cancer.

Thiel A, Ristimäki A.

APMIS. 2015 May;123(5):365-72. doi: 10.1111/apm.12359. Epub 2015 Feb 23. Review.

PMID:
25706252
44.

T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.

Taipale K, Liikanen I, Juhila J, Karioja-Kallio A, Oksanen M, Turkki R, Linder N, Lundin J, Ristimäki A, Kanerva A, Koski A, Joensuu T, Vähä-Koskela M, Hemminki A.

Mol Ther. 2015 May;23(5):964-973. doi: 10.1038/mt.2015.17. Epub 2015 Feb 6. Erratum in: Mol Ther. 2016 Jun;24(6):1159.

45.

Exome sequencing reveals three novel candidate predisposition genes for diffuse gastric cancer.

Donner I, Kiviluoto T, Ristimäki A, Aaltonen LA, Vahteristo P.

Fam Cancer. 2015 Jun;14(2):241-6. doi: 10.1007/s10689-015-9778-z.

PMID:
25576241
46.

Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma.

Thiel A, Moza M, Kytölä S, Orpana A, Jahkola T, Hernberg M, Virolainen S, Ristimäki A.

Hum Pathol. 2015 Feb;46(2):169-75. doi: 10.1016/j.humpath.2014.08.018. Epub 2014 Oct 30.

PMID:
25442222
47.

Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry.

Nummela P, Saarinen L, Thiel A, Järvinen P, Lehtonen R, Lepistö A, Järvinen H, Aaltonen LA, Hautaniemi S, Ristimäki A.

Int J Cancer. 2015 Mar 1;136(5):E282-9. doi: 10.1002/ijc.29245. Epub 2014 Oct 13.

48.

Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?

Molander P, Färkkilä M, Ristimäki A, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A, Rautiainen H, Nissinen M, Haapamäki J, Arkkila P, Nieminen U, Kuisma J, Punkkinen J, Kolho KL, Mustonen H, Sipponen T.

J Crohns Colitis. 2015 Jan;9(1):33-40. doi: 10.1016/j.crohns.2014.06.012.

PMID:
25052347
49.

Comparison of serial debulking and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei of appendiceal origin.

Järvinen P, Ristimäki A, Kantonen J, Aronen M, Huuhtanen R, Järvinen H, Lepistö A.

Int J Colorectal Dis. 2014 Aug;29(8):999-1007. doi: 10.1007/s00384-014-1933-8. Epub 2014 Jun 26.

PMID:
24965858
50.

Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy.

Ålgars A, Avoranta T, Österlund P, Lintunen M, Sundström J, Jokilehto T, Ristimäki A, Ristamäki R, Carpén O.

PLoS One. 2014 Jun 18;9(6):e99590. doi: 10.1371/journal.pone.0099590. eCollection 2014.

Supplemental Content

Loading ...
Support Center